

MANAGEMENT REPORT for the nine months of 2020



SOPHARMA GROUP

30.11.2020

Content:

I.	General information about Sopharma Group	3
	1. Main activities	3
	2. Registration and activity of the Company	3
	3. Controlled companies	4
	4. Board of directors.....	5
	5. Shareholder structure as at 30 September 2020	6
	6. Employees	6
II.	Recent developments.....	6
	1. Industrial activity	6
	2. Distribution.....	8
	3. Revision of the activities of the Group and the main risks it faces	8
	4. Analysis of the activities	12
	5. Significant events in the nine months of 2020 and until the date of the interim consolidated management report	24
	6. Transactions with related parties.....	31
III.	Information about the shares of “Sopharma” AD.....	31

I. General information about Sopharma Group

1. Main activities

Sopharma Group (the Group) is a leading Bulgarian producer, exporter and local distributor of pharmaceutical products with a strong presence in Eastern and South-eastern Europe, offering a wide range of prescription medicines and OTC products, food supplements, cosmetics and medical devices.

The Group operates in the following areas:

- production of pharmaceutical products including medicines, primarily generics, herbal-based substances and food supplements, which is mainly done by “Sopharma” AD (the Company);
- production of medicinal products and medicinal cosmetics, as plasters, bandages and sanitary-hygiene products focused at the production site in Sandanski city;
- distribution of pharmaceuticals, medical supplies, sanitary materials, vitamins, food supplements and cosmetics, which is mainly performed by “Sopharma Trading” in Bulgaria and Serbia.
- production and distribution of non-pharmaceutical products, primarily medical supplies such as syringes and other disposables used in medicine, which is mainly performed by “Momina Krepost” AD, and other complementary activities to the production of pharmaceutical products and distribution of pharmaceutical products.

2. Registration and activity of the Company

“Sopharma” AD is a company registered in Bulgaria under the Provisions of the Commercial Law, with its registered office in Sofia, 16 Iliensko shose str.

“Sopharma” was established in 1933. The court registration of the Group is from 15 November 1991, decision №1/1991 of Sofia City Court. “Sopharma” AD is a public company under the Law on Public Offering of Securities.

The Group conducts the production and marketing of medicinal substances and dosage forms; research, engineering and implementation activities in the field of phytochemistry, chemistry and pharmacy, production of medical devices and cosmetic products, incl. - plasters, dressings, sanitary- hygienic products, medical cosmetics, concentrates for hemodialysis. “Sopharma” AD provides services related to production, as well as to ancillary and supporting

activities.

3. Controlled companies

Sopharma Group consists of “Sopharma” AD and its forty-nine subsidiaries, directly or indirectly controlled by the Company. Additionally, the Group has investments in one associated company.

Company	Interest as at 30.09.2020 in %
“Sopharma Trading” AD, Sofia, Bulgaria*	76.09
“Biopharm Engineering” AD, Sliven, Bulgaria	97.15
“Pharmalogistica” AD, Sofia, Bulgaria	89.39
“Elektroncommerce” EOOD, Sofia, Bulgaria	100.00
“Sopharma Buildings” REIT, Sofia, Bulgaria	40.38
“Momina Krepost” AD, Veliko Tarnovo, Bulgaria	63.12
“Phyto Palauzovo” AD, Kazanluk, Bulgaria**	95.00
“Sopharmacy” EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 2” EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 3” EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 4” EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 5” EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 6” EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 7” EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 8” EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 9” EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 10” EOOD, Sofia, Bulgaria**	76.09
“Veta Pharma” AD, Veliko Tarnovo, Bulgaria	99.98
“Aromania” AD, Sofia, Bulgaria	76.00
“Sopharmacy 11” (PharmaStore 1) EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 12” (PharmaStore 2) EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 13” (PharmaStore 3) EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 14” (PharmaStore 4) EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 15” (PharmaStore 5) EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 16” EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 17” EOOD, Sofia, Bulgaria**	76.09
“Sopharmacy 18” EOOD, Sofia, Bulgaria**	76.09
PAO “Vitamini”, Uman, Ukraine	100.00

4

This is a translation from Bulgarian of the Management report of Sopharma Group for the nine months of 2020.

In case of divergence Bulgarian text should prevail.

Sopharma Group

“Sopharma” Poland Sp. z. o. o, Warsaw, Poland in Liquidation	60.00
“Sopharma” Warsaw Sp. z. o. o, Warsaw, Poland	100.00
“BRIZ SIA”, Riga, Latvia	68.14
Brititrade SOOO, Minsk, Belarus**	54.51
“Tabina” SOOO, Minsk, Belarus **	54.66
OOO “Sopharma” Ukraine, Kiev, Ukraine	100.00
OOO “Pharmacist Plus”, Minsk, Belarus**	40.26
OOO “Bellerofon”, Minsk, Belarus***	58.46
TOO “Sopharma” Kazakhstan, Almaty, Kazakhstan	100.00
ZAO “Interpharm”, Vitebsk, Belarus***	61.33
OOO “Galenapharm”, Pinsk, Belarus**	61.73
ODO “Medjel”, Minsk, Belarus**	55.87
ODO “Alenpharm-Plus”, Belarus**	62.68
ODO “Salius Line”, Grodno, Belarus**	52.47
“Rap Pharma International” OOD, Kishinev, Moldova	80.00
“Sopharma Trading” D.o.o., Sabac, Serbia**	76.09
OOO “Zdorovei”, Minsk, Belarus**	45.55
BOOO “SpetzApharmacia”, Bobruisk, Belarus**	47.70
UAB “Recessus”, Kaunas, Lithuania**	34.74
OOO “Zdorovei Pharm”, Minsk, Belarus**	29.61
“Pharmachim” EOOD, Belgrad, Serbia	100.00

*effective interest in percent


**indirect interest

***joint venture

4. Board of directors

“Sopharma” AD has a one tier management system with a Board of Directors of five members as follows: Ognian Donev, PhD - Chairman and members Vessela Stoeva, Alexander Tchaoushev, Ognian Palaveev and Ivan Badinski. As of 16 June 2020, Mr. Simeon Donev, Business Development Director at “Sopharma” AD, was appointed as procurator of the company. The Company is represented and managed by the Executive Director Ognian Donev, PhD. The company is represented and managed by the Executive Director Ognian Donev, PhD.

5. Shareholder structure as at 30 September 2020



- "Donev Investments Holding" AD
- "Telecomplect invest" AD
- "Sopharma" AD (treasury shares)
- "Rompharm Company" OOD
- CUPF "Alianz Bulgaria"
- Other legal persons
- Other physical persons

6. Employees

As at 30 September 2020, the average number of employees of Sopharma Group is 5 097 (compared to 5 163 in 2019). The average number of employees of "Sopharma" AD as at 30 September 2020 is 2 098 (at 2 275 in 2019) and of "Sopharma Trading" AD is 757 (compared to 833 in 2019).

II. Recent developments

1. Industrial activity

The company and its production subsidiaries have 12 pharmaceutical plants in Bulgaria, complied with EU Good Manufacturing Practices (GMP), a factory in the Ukraine, certified by local authorities and recognized in all CIS countries.

The production activities of the Group are carried out and developed in the following areas:

- production of pharmaceutical products;
- substances and preparations based on plant raw materials (phytochemical production);
- veterinary vaccines;
- infusion solutions;
- concentrates for hemodialysis;

- medical disposable products for human and veterinary medicine;
- injection molded products for the industry, agriculture and households.

“Sopharma” AD

The Company has more than 200 products in its portfolio: incl. nearly 190 medicinal products and 11 groups of medical devices. Medicinal products mainly include generics and 15 traditional products, 12 of which are plant-based. The traditional products of the Group (and in particular Tabex, Carsil and Tempalgin) make a major contribution to its export market income, while the company's generic products are of major importance for domestic sales, Analgin being the leader among these products.

The product portfolio of “Sopharma” AD focuses on the following therapeutic areas: cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory tract and asthma, neurology and psychiatry, urology and gynecology, nephrology, surgery, orthopedics and traumatology.

The most significant products in terms of their contribution to the revenues are:

- Carsil – traditional plant-based product used to treat gastroenterological diseases (liver diseases);
- Tempalgin - traditional analgesic (painkiller);
- Tabex - traditional plant-based smoking cessation drug;
- Tribestan - traditional plant-based product that stimulates the functions of the sexual system;
- Broncholitin - traditional plant-based product used to suppress cough;
- Analgin - generic analgesic (pain reliever);
- Nivalin - traditional plant-based product used for diseases of the peripheral nervous system;
- Methylprednisolone - a generic medicine for cases of severe allergies and certain life-threatening conditions;
- Vitamin C - food supplement with wide application;
- Valeriana - a generic non-prescription herbal medicine used to reduce the stress;
- Medical devices - gauzes, compresses and dressings.

2. Distribution

“Sopharma Trading” AD

The company is a leading distributor of pharmaceutical products and cosmetics in Bulgaria with a market share in the pharmaceutical products segment of 22.7% (according to IQVIA). “Sopharma Trading” is the exclusive distributor on the Bulgarian market of particular pharmaceutical products of several leading international pharmaceutical and other companies in the field of healthcare such as Amgen, Astra Zeneca, GE Healthcare, Johnson and Johnson, Abbot Diagnostics, Hartmann, Novartis and Novo Nordisk.

The Group has more than 15 000 products (particularly pharmaceutical products, medical equipment and devices, accessories, cosmetics, vitamins and food supplements) in its portfolio, including the brands of “Sopharma” AD, and holds exclusive rights for Bulgaria over brands of strategic partners such as “Aboca”, “Colief”, “Jamieson”, “Planter's”, “Premax”, “Skincode”, “SVR” Laboratories, “US Pharmacia” and “Wyeth”, specialized services (such as software solutions for pharmacies and advice and consulting services) and national logistics services. “Sopharma Trading” AD cooperates with more than 400 partners and over 3 000 clients.

3. Revision of the activities of the Group and the main risks it faces

COVID-19

On March 11, 2020, the World Health Organization declared a pandemic of the coronavirus, subsequently the Government of the Republic of Bulgaria, announced various measures to limit the infection. Measures introduced include: work from home, temporary closure of schools, universities, restaurants, cinemas, theaters, museums and sports facilities, retailers, excluding food retailers, grocery stores and pharmacies.

The management of “Sopharma” AD carefully analyzes the potential effects of the pandemic and the restrictions imposed by the government, and is expected to reduce overall economic activity and liquidity in the country's economy, which is expected to affect the Company's operations.

The effects on the activity of the Company as a result of the occurred events may include: reduction of the revenues, extraordinary expenses, delay with the implementation of projects, planned investments, etc.

Based on publicly available information at the date of the financial statements, Management has taken action to limit the adverse effects of pandemic events, which include:

- Ensuring continuous operation in compliance with measures to limit the spread of COVID-19, including - strict throughput and temperature measurement of employees and visitors, prohibition of crowding and distribution of jobs in the production in an appropriate manner that ensures the absence of close contact between employees, separation of traffic flows in buildings and in the spaces between them, etc .;
- Negotiations with suppliers to maintain the rhythm of receipt of raw materials and materials, as well as to meet the needs of the company for specific raw materials dictated by the demand for specific drugs and medical supplies needed to deal with the pandemic;
- Providing information to customers on how to work in order to maintain delivery schedules of goods;
- Negotiations with the financial institutions, partners of the Company and the provision of adequate information to them in order to allow timely additional financing in case of need or at some enterprises in the Group, postponement of loan payments, if necessary, to guarantee cash flows and others.

Management considers the going concern principle to be appropriate for these consolidated financial statements, as the Company as a whole has sufficient liquid resources to continue in the foreseeable future. As at the date of these consolidated financial statements, the management of the Company does not intend to discontinue certain activities.

Risks related to the Group's business and the industry the Group operates in

- The Group faces significant competition;
- Part of Sopharma Trading's revenues in Bulgaria is generated from sales to state hospitals, which predetermines a high degree of business risk;
- The Group is dependent on regulatory approvals;
- Government regulations affecting the Group's business may change, thus possibly increasing compliance costs or otherwise affecting its operations;

- Part of the Group's revenues, in particular in Bulgaria, depend on the inclusion of the Group's medicines in reimbursement lists;
- The Group's production facilities and processes are subject to strict requirements and regulatory approvals that may delay or disrupt the Group's operations;
- The Group's ability to pay dividends depends on a number of factors and there can be no assurance that the Group will be able to pay dividends in accordance with its dividend policy or at all in any given year;
- The Group is subject to operational risk, which is inherent to its business activities;
- The Group is subject to numerous environmental and health and safety laws and regulations and is exposed to potential environmental liabilities;
- Litigation or other out-of-court proceedings or actions may adversely affect the Group's business, financial condition and results of operations.

Risks related to Bulgaria and other markets in which the Group operates

- The macroeconomic environment, particularly in Bulgaria, Russia and Ukraine, has a significant effect on the Group's operations and position;
- The political environment in Bulgaria has a significant effect on the Group's operations and financial condition;
- The political environment in the Group's export markets, especially in Russia, Belarus and the Ukraine, has a significant effect on the Group's operations and financial condition;
- Risks related to the Bulgarian legal system;
- Developing legal frameworks in some countries in which the Group sells its products, in particular Russia, Belarus and the Ukraine, may negatively impact the Group's operations in these countries;
- Risks relating to exchange rates and the Currency Board in Bulgaria;
- Interpretations of tax regulations may be unclear and tax laws and regulations applicable to the Group may change.

Currency risk

The Group companies perform their activities in active exchange with foreign suppliers and customers and are therefore exposed to currency risk.

Through the companies in Belarus and Ukraine, the group carries out business operations in these countries and, accordingly, has substantial exposures in Belarusian rubles and Ukrainian

hryvnia. The currency risk is related to the negative movement of the exchange rates of these currencies against the Bulgarian lev in the future business operations, the recognized assets and liabilities in foreign currency and the net investments in foreign companies. The rest of the companies abroad sell mainly on local markets, leading to currency risk and against their currencies – the Serbian Dinar and the Polish zloty.

In order to control the currency risk, a system of planning of import deliveries, for foreign currency sales, as well as procedures for daily monitoring of movements in the dollar exchange rate and for control of forthcoming payments is introduced. The exposures of the subsidiaries in Bulgaria in foreign currency is insignificant, as almost all sales are made on the local market in Bulgarian leva.

Imports of goods are fully realized in euro. Borrowings when denominated in foreign currency are mainly denominated in euro.

4. Analysis of the activities

Key financial indicators

Indicator	1-9/2020 BGN '000	1-9/2019 BGN '000	Change %
Revenues from sales	1 018 446	924 776	10.1%
EBITDA	65 559	73 603	-10.9%
Operating profit	32 818	40 989	-19.9%
Net profit	17 514	36 867	-52.5%
CAPEX*	32 081	43 297	-25.9%
	30.09.2020	31.12.2019	
	BGN '000	BGN '000	
Non-current assets	583 066	626 172	-6.9%
Current assets	599 859	549 100	9.2%
Owners' equity	575 705	575 772	0.0%
Non-current liabilities	94 428	115 448	-18.2%
Current liabilities	512 792	484 052	5.9%

*acquired tangible and intangible fixed asset

Indicator	1-9/2020	1-9/2019
EBITDA/Sales revenues	6.4%	8.0%
Operating profit / Sales revenues	3.2%	4.6%
Net profit/Sales revenues	1.7%	4.0%
	30.09.2020	30.06.2020
Attracted capital / Equity	1,05	1,03
Net debt/EBITDA on annual basis	4,0x	3,7x

* net debt includes bank loans and leasing and factoring liabilities less cash, taking into account the effects of the adoption of IFRS 16 Leasing, effective from 1 January 2019.

Revenue from sales

Revenue from sales of the Group increase with BGN 93,7 million or 10%, reaching BGN 1 018,5 million in the nine months of 2020 compared to BGN 924,8 million in the nine months of 2019. Sales of goods increased with BGN 95,4 million or 13%, reaching BGN 824,8 million in the nine months of 2020 compared to BGN 729,4 million in the nine months of 2019. Sales of finished


12

This is a translation from Bulgarian of the Management report of Sopharma Group for the nine months of 2020.

In case of divergence Bulgarian text should prevail.

products decrease by BGN 1,7 million, or 1%, to BGN 193,7 million in the nine months of 2020 compared to BGN 195,4 million in the nine months of 2019.

Geographical distribution of sales revenues



The contribution of sales in Bulgaria to the consolidated sales revenue in the nine months of 2020 amounted to 66%, increasing by 12% compared to the nine months of 2019. Sopharma has a 3% share on the Bulgarian pharmaceutical market in terms of value and a 11% share in terms of sold quantity (units). The positions of the main competitors of the Company in the country are as follows: Roche – 6.8% (0.2% in units), Novartis—6.8% (3.8% in units), Actavis – 4.3% (10% in units), Merck Sharp Doh– 4.3% (0.8% in units), Pfizer – 4% (1% in units), Abbvie – 3.8% (0% in units), Astrazeneca – 2.9% (0.4% in units), Glaxosmithkline – 2.8% (2.4% in units), Sanofi-Aventis – 2.6% (2% in units).


Revenues from sales of the Group in Europe amount to 33% of total consolidated sales revenues for the nine months of 2020 and increase with 7% compared to the nine months of 2019.

Sales by type of formulation

The reported revenue of the Group includes the following items - revenues from the sale of finished products and revenues from the sale of goods.


Revenues from the sale of finished products includes revenues from the sale of products produced by the Company and the companies in the Group.

Revenues from sales of finished products	1-9/2020	1-9/2019	Change
	BGN '000	BGN '000	
Tablet dosage forms	129 622	135 241	-4%
Ampoule dosage forms	23 747	22 263	7%
Consumables, dressing materials and apparatuses	9 426	9 158	3%
Unguents	6 973	6 443	8%
Syrup dosage forms	5 955	7 069	-16%
Lyophilic products	5 397	4 688	15%
Drops	1 089	735	48%
Veterinary vaccines	1 032	560	84%
Hemodialysis concentrates	1 017	1 205	-16%
Other	9 393	7 999	17%
Total	193 651	195 361	-1%



Revenues from sales of goods include revenues from sales of goods to third parties distributed mainly by "Sopharma Trading" AD, SIA "Briz" and SOOO "Brititrade".

Revenue earned from sale of goods	1-9/2020	1-9/2019	Change %
	BGN '000	BGN '000	
Tablet dosage forms	399 317	345 034	16%
Ampoule dosage forms	166 132	145 082	15%
Syrup dosage forms	61 894	62 261	-1%
Consumables, dressing materials and apparatuses	43 508	42 395	3%
Drops	37 191	43 820	-15%
Unguents	36 793	26 743	38%
Cosmetic products	28 489	19 984	43%
Infusion solutions	9 858	6 275	57%
Other	41 613	37 821	10%
Total	824 795	729 415	13%



Other operating revenues

Other revenues	1-9/2020	1-9/2019	Change %	Rel. share 2020 %
	BGN '000	BGN '000		
Services rendered	3 959	5 622	-30%	52%
Government funding	713	594	20%	9%
Rents	675	541	25%	9%
Profit from sale of fixed assets	582	227	156%	8%
(Losses) / gains on foreign exchange from trade receivables and payables and current accounts	(397)	1 805	-122%	-5%
Revenues from fines and penalties	293			4%
Services related to social activities and events	199	772	-74%	3%
Interests on current accounts	126	67	88%	2%
Profit from sale of materials	123	40	208%	2%
Derecognition of liabilities	92	761	-88%	1%
Other income	1 234	1 155	7%	16%
Total other operating income	7 599	11 584	-34%	100%

Other operating income decreased by BGN 4 million to BGN 7,6 million in the nine months of 2020 compared to BGN 11,6 million in the nine months of 2019, mainly as a result of a decrease in the services rendered by BGN 1,7 million, as well as the losses from exchange rate differences on trade receivables and payables and current accounts in the amount of BGN 0,4 million in the nine months of 2020, as the net decrease is BGN 2,2 million compared to the nine months of 2019. The losses from currency differences are a result of the devaluation of local currencies in Belarus and Kazakhstan.

Operating expenses

Operating expenses	1-9/2020	1-9/2019	Change	Rel. share of
	BGN '000	BGN '000	%	expenses 2020
				%
Changes in inventories of finished goods and work in progress	(9 357)	1 207	-875%	-1%
Materials	67 016	66 766	0%	7%
External services	55 823	54 290	3%	6%
Personnel	95 200	94 691	1%	10%
Depreciation and amortization	32 741	32 614	0%	3%
Carrying amount of goods sold	742 556	639 664	16%	75%
Other operating expenses	9 248	6 139	51%	1%
Total operating expenses	993 227	895 371	11%	100%

Operating expenses increase by BGN 97,9 million or by 11% from BGN 895,4 million in the nine months of 2019 to BGN 993,2 million in the nine months of 2020.

The book value of goods sold has the largest share in operating expenses (75%) and its increase by 16% exceeds the growth of revenues from goods sold, which amounts to 13%. For the other operating expenses there is no significant change in absolute values compared to the previous period, as the change in the stocks of finished products and work in progress indicate optimization of operating costs, respectively in the cost of finished products.

For the current period more significant changes are reported in the structure of expenses for external services, where the expenses for advertising and marketing services decreased by BGN 4,2 million, and the expenses for service charges increased by BGN 5 million for the activity the change is due to a reported by BGN 3 million more marriage of tangible fixed assets. For other


operating expenses, the change is due to a reported more waste of tangible fixed assets with BGN 3 million.

Financial income and costs

Finance income	1-9/2020	1-9/2019	Change	Rel. share of expenses in 2020
	BGN '000	BGN '000	%	%
Income on loans extended	2 060	1 962	5%	59%
Interest income on overdue trade receivables	1 163	1 964	-41%	33%
Net profit from operations with investments in securities	91	269	-66%	3%
Interest on receivables under special contracts	70	58	21%	2%
Income from equity (dividends)	66	192	-66%	2%
Interest income on bank deposits	16	1	1500%	0%
Recovered impairment for credit losses of cash	12	-	-	0%
Net profit from exchange differences on receivables from the sale of a subsidiary	-	171	-100%	0%
Net change in the impairment adjustment for credit losses on trade receivables	-	85	-100%	0%
Net foreign exchange gains on foreign currency loans and leases	-	871	-100%	0%
Total	3 478	5 573	-38%	100%
Finance costs			Change	Rel. share of costs in 2020
Interest expenses on loans received	7 640	6 811	12%	49%
Net foreign exchange loss on foreign currency loans and leases	5 448	-	-	35%
Lease interest expenses	1 139	1 456	-22%	7%
Bank fees on loans and guarantees	610	739	-17%	4%
Interest expense under factoring agreement	433	342	27%	3%
Provision for financial guarantees	250	231	8%	2%
Deregistered capital of a company in the scope of long-term capital investments	25	-	-	0%
Net change in the impairment adjustment for credit losses on trade receivables	8	-	-	0%
Expenses for other interest	-	6	-100%	0%
Total	15 553	9 585	62%	100%

Financial income and expenses in the nine months of 2020 change most significantly as a result of the registered net foreign exchange loss on foreign currency loans and lease agreements of BGN 5,4 million, which is mainly due to the impairment of the Belarusian ruble and its effect on the debt exposure in euros and dollars of the Group companies in Belarus.

Financial result



Earnings before interest, taxes and depreciation (EBITDA) decrease by BGN 8 million or by 11%, while in the nine months of 2020 it amounted to BGN 65,6 million compared to BGN 73,6 million in the nine months of 2019. The main reason is the decrease in the gross profit margin of goods sold, which decreased to 10% for the nine months of 2020 compared to 12.3% for the nine months of 2019.

Profit from operating activities decreased by BGN 8,2 million or by 20%, to BGN 32,8 million in the nine months of 2020 compared to BGN 41 million in the nine months of 2019.

Net profit decreased by BGN 19,4 million or 53% to BGN 17,5 million in the nine months of 2020 compared to BGN 36,9 million in the nine months of 2019, as in addition to the stated factors at the operational level, the increased financial expenses as a result of losses from exchange rate differences have a negative impact, as well as the one-time effect of the profits reported in the previous period from associates.

Assets

	30.09.2020	31.12.2019	Change	Rel. share 2020
	BGN '000	BGN '000	%	%
Non-current assets				
Property, plant and equipment	361 548	378 625	-5%	62%
Intangible assets	43 193	42 829	1%	7%
Goodwill	15 589	15 909	-2%	3%
Investment property	11 277	10 856	4%	2%
Investments in associated companies and joint ventures	65 340	62 985	4%	11%
Other long - term equity investments	13 810	10 079	37%	2%
Long-term receivables from related parties	59 241	91 794	-35%	10%
Other long-term receivables	11 382	10 674	7%	2%
Deferred tax assets	1 686	2 421	-30%	0%
	583 066	626 172	-6.9%	49%
Current assets				
Inventories	241 683	229 873	5%	40%
Trade receivables	285 088	255 660	12%	48%
Receivables from related parties	6 058	7 112	-15%	1%
Assets held for sale	1 462	1 462		
Other short-term receivables and assets	43 602	27 480	59%	7%
Cash and cash equivalents	21 966	27 513	-20%	4%
	599 859	549 100	9.2%	51%
TOTAL ASSETS	1 182 925	1 175 272	0.7%	100%

Total assets increase by BGN 7,6 million or by 1%, from BGN 1 175,3 million as at 31.12.2019 to BGN 1 182,9 million as at 30.09.2020, mainly due to an increase in the current assets.

Non-current assets decrease by BGN 43,1 million or by 7%, mainly due to a decrease in long-term receivables from related companies by BGN 32,6 million as a result of partial repayment of loans from companies from the group of "Doverie - Obedinen Holding" AD.

Current assets increase by BGN 50,8 million or 9%, to BGN 599,9 million as at 30.09.2020 compared to BGN 549,1 million as at 31.12.2019 in the part of trade receivables with BGN 29,4 million, inventories by BGN 11,8 million and other short-term receivables and assets by BGN 16,1 million.

Liabilities and owners' equity

EQUITY	30.09.2020	31.12.2019	Change	Rel. share
	BGN '000	BGN '000	%	from owners' equity 2020 %
Equity attributable to owners of the parent company				
Share capital	134 798	134 798	0%	23%
Reserves	64 199	60 977	5%	11%
Retained earnings	362 856	360 656	1%	63%
	561 853	556 431	1%	98%
NON-CONTROLLING INTEREST	13 852	19 341	-28%	2%
TOTAL EQUITY	575 705	575 772	0%	100%
LIABILITIES	30.09.2020	31.12.2019	Change	Rel. share
	BGN '000	BGN '000	%	from total liabilities %
Non-current liabilities				
Long-term bank loans	38 523	56 832	-32%	6%
Deferred tax liabilities	7 281	8 196	-11%	1%
Long-term liabilities to related parties		2 972	-100%	0%
Long-term liabilities to personnel	6 735	6 626	2%	1%
Finance lease liabilities	27 398	25 840	6%	5%
Government grants	10 558	10 940	-3%	2%
Other non-current liabilities	3 933	4 042	-3%	1%
	94 428	115 448	-18%	16%
Current liabilities				
Short-term bank loans	256 366	274 829	-7%	42%
Short-term of long-term bank loans	32 563	16 730	95%	5%
Trade payables	135 139	116 407	16%	22%
Payables to related parties	4 644	7 668	-39%	1%
Payables on contract for factoring	38 685	24 772	56%	6%
Short-term part of leasing liabilities	12 236	10 012	22%	2%
Payables to the personnel and for social security	14 858	15 418	-4%	2%
Tax payables	7 330	7 217	2%	1%
Other current liabilities	10 971	10 999	0%	2%
	512 792	484 052	6%	84%

This is a translation from Bulgarian of the Management report of Sopharma Group for the nine months of 2020.

In case of divergence Bulgarian text should prevail.

Sopharma Group

TOTAL LIABILITIES	607 220	599 500	1%	100%
TOTAL EQUITY AND LIABILITIES	1 182 925	1 175 272	0.7%	

The equity of Sopharma Group decreases by BGN 0,1 million compared to 31.12.2019, mainly due to a decrease of non-controlling interest by BGN 5,5 million, as a result of the negative financial results for the nine months of the subsidiaries in Latvia and Belarus, mainly due to the depreciation of the local currency.

Non-current liabilities decrease by BGN 21 million or 18%, from BGN 115,4 million at the end of 2019 to BGN 94,4 million at 30.09.2020, mainly from decrease in long-term bank loans by BGN 18,3 million and long-term liabilities to related parties by BGN 3 million.

Current liabilities increase by BGN 28,7 million or by 6% compared to the end of 2019, mainly due to an increase of trade liabilities by BGN 18,7 million, as well as of short-term part of long-term bank loans by BGN 15,8 million, obligations under factoring contracts with BGN 13,9 million. There is a decrease of short-term bank loans by BGN 18,5 million. Total liabilities on bank loans, leasing and factoring of the Group decrease by BGN 3,2 million compared to the end of 2019, with the net debt after deduction of cash and cash equivalents increase by BGN 2,3 million.

Cash flow

	30.09.2020	30.09.2019
	BGN '000	BGN '000
Net cash flows from operating activities	(141 077)	(114 951)
Proceeds of amounts by factoring	178 341	(149 945)
Purchases of property, plant and equipment and intangible assets	(24 430)	(27 369)
Free cash flow (normalized)	18 834	6 826

The free cash flow (normalized with factoring revenues) generated for the nine months of 2020 amounts to BGN 18,8 million compared to BGN 6,8 million in the nine months of 2019.

Ratios

	30.09.2020	30.06.2020
ROE ¹	12.2%	15.7%
ROA ²	5.7%	7.3%
Asset turnover ³	1,16	1,15
Current liquidity ⁴	1,17	1,21
Quick ratio ⁵	0,70	0,71
Cash/current liabilities ⁶	0,04	0,04
Owners' equity/liabilities ⁷	0,95	0,97

¹ Net profit on an annual basis attributable to equity holders of the Company / arithmetic mean of non-minority interest for the last five quarters

² Net profit on an annual basis attributable to equity holders of the Company / arithmetic mean of total assets for the last five quarters

³ Revenue from sales on an annual basis / arithmetic mean of total assets over the last five quarters

⁴ Current assets / current liabilities

⁵ Receivables + Cash / Current liabilities

⁶ Cash / Current liabilities

⁷ Own capital / Liabilities

New developments and products

- New Products for the period January - September 2020:
 - During the reporting period, a Marketing Authorization was obtained for a new medicinal product - Solifenax 5 mg film-coated tablet (Bulgaria).
- New medicinal products introduced into production:
 - During the reporting period the following new medicinal products were introduced into the production: - Paracedol Kids 120 mg / 5 ml oral suspension; Antiemetin 5 mg / ml solution for injection; Promerol 1 mg / ml solution for injection and food supplement Alovital oral solution 2.5 mg 5ml.
- New registrations and re-registrations / changes:

New registrations

- Received 25 Authorizations for the use of medicinal products for new destinations, namely:
 - Pyraminol 800 mg film-coated tablet (Armenia);
 - Sophalor 5 mg film-coated tablet (Azerbaijan);
 - Indometacin Sopharma 100 mg suppositories (Azerbaijan);

- Deavit Neo 0.5 mg/ml oral drops, solution (Azerbaijan);
 - Otoflox 40 mg/g+10 mg/g ear drops, solution (Azerbaijan);
 - Sophalor 0.5 mg/ml oral solution (Azerbaijan);
 - Sydnopharm 2 mg tablet (Azerbaijan);
 - Sophintesif 1.5 mg prolonged-release tablets (Azerbaijan);
 - Methadone Sopharma 10 mg/ml oral solution (Bosnia and Herzegovina);
 - Analgin Kids 500 mg/ml oral drops, solution (Djordjia);
 - Verapamil Sopharma 2.5 mg/ml solution for injection (Iran);
 - Valeriana 30 mg film-coated tablet (Kazakhstan);
 - Broncholytin Ivy 7 mg/ml syrup (Kyrgyzstan);
 - Abrolytin 15 mg/ 5 ml syrups (Kyrgyzstan);
 - Feloran gen 1 g/100 g gel (Kyrgyzstan);
 - Sophalor 0.5 mg/ml oral solution (Kyrgyzstan);
 - Adrenaline Sopharma 1 mg/ml solution for injection (Malta);
 - Carsil Max 110 mg hard capsules (Mongolia);
 - Troxerutin gel Sopharma 2 g/100 g gel (Mongolia);
 - Troxerutin gel Sopharma 300 mg hard capsules (Mongolia);
 - Dexamethasone Medszo 4 mg/ml solution for injection (Portugal)
 - Tuspan 7 mg/ml syrup (Russia);
 - Felogel 1% gel (Serbia);
 - Amlodipine Sopharma 5 mg tablet (Serbia);
 - Sophamet 850 mg film-coated tablet (Tunisia).
- Documentation for the registration of 44 medicinal products to agencies of new destinations was submitted.

Food additives:

- During the reporting period, 13 food supplements for Bulgaria, Armenia, Azerbaijan, Kazakhstan and Kyrgyzstan was notified.

Medical supplies:

- 18 medical supplies were registered in Ukraine (two) and Macedonia (sixteen).

Re-registrations / changes:

- Updated Authorizations for use of 70 medicinal products.

- Submission of documentation for the renewal of the Marketing Authorizations for 101 medicinal products to agencies.
- 680 changes for medicinal products approved by agencies.
- 749 changes made for medicinal products to the agencies.

Developments:

- There is a pharmaceutical development of 8 new medicinal products.
- 19 medicinal products/ active substances have been transferred / undergoing transfer and 24 manufacturing processes / technologies have been validated / optimized.

5. Significant events in the nine months of 2020 and until the date of the interim consolidated management report

- On 22 January 2020, “Sopharma” AD began to pay the gross dividend of 5 stotinki per share voted at the General Meeting of Shareholders on 13 December 2019. The persons registered in the “Central Depository” AD as shareholders on the 14th day after the day of the General Meeting, namely 27 December 2019 have a right to dividend.
- On 31 January 2020 a merger of SOOO “Brizpharm”, Belarus into OOO “Bellerofon”, Belarus was registered, by merging the assets and liabilities of the two companies. The activity of the merged company SOOO “Brizpharm”, Belarus is terminated and all its rights and obligations at the time of the merger are assumed by OOO “Bellerofon”, Belarus.
- As of 2 March 2020, OOO “Zdorovey Pharm”, Belarus is a subsidiary through OOO “Zdorovey”, Belarus, as OOO “Zdorovey” owns 65% of the capital of OOO “Zdorovey Pharm”.
- On 19 March 2020, “Sopharma Trading” AD announced the conclusion of a contract for the acquisition of the SCS Franchise pharmacy group. The merger of “Sopharmacy” and SCS Franchise will provide a stronger market position and an opportunity to even more meet the growing needs of Bulgarian patients for quality health services. The merger will also bring national expansion of the operations of “Sopharma Trading” AD in the retail segment of the pharmacy market. The Commission for Protection of Competition is about to rule on the deal.
- On 14 April 2020, the company Pharmachim EOOD, Serbia, was established. Sopharma AD owns 100% of the company's shares.

- On 22 April 2020, “Sopharma” AD received BGN 30 million, which were paid interest and loans from an associated company and a company controlled by it (“Doverie - Obedinen Holding” AD and “Doverie Invest” AD).
- On 5 June 2020 the Annual General Meeting of “Sopharma” AD was held, at which the following decisions were taken: The AGM approves the Annual Report of the Board of Directors on the company's activities in 2019.; The AGM approves the Annual Report of the Investor Relations Director for 2019; The AGM approves the Audited Annual Financial Statements /Individual and Consolidated/ of the Company for 2019.; The AGM approves the Auditor's Reports on the Audit of the Annual Individual Financial Statements and of the Annual Consolidated Financial Statements of the Company for the year 2019; The AGM approves the proposal of the Board of Directors for the distribution of the Company's 2019 profit of BGN 40 382 210.24 as follows: allocating 10% or BGN 4 038 221.02 to the mandatory reserve, BGN 6 284 221.60 for the 2019 six-month preliminary dividend. After dividing the legal reserve by 10% and dividend paid in advance for the half year of 2019, to distribute a gross dividend of BGN 0.07 per share (seven stotinki). The amount remaining after the distribution above and the retained earnings from previous years in the amount of BGN 1 995 956.93 shall be transferred to additional reserves of the company.; The AGM approves the Audit Committee’s report on its activities in 2019.; The AGM re-elects the current members of the Audit Committee of the company for a new term of three years.; The AGM releases the members of the Board of Directors from responsibility for their activities in 2019.; The AGM selects "Baker Tilly Klitou and Partners" OOD as a registered auditor for 2020; The General Meeting approves the Report of the Board of Directors on the implementation of the Remuneration Policy of the Members of the Board of Directors of the Company for 2019.; The AGM decided the constant remuneration of the members of the Board of Directors and the constant remuneration of the Executive Director in 2020 remain unchanged.; Pursuant to art. 24, para 3, letter B of the Articles of Association, the Executive Director of the Company shall be paid an additional remuneration of 1% (one percent) of the amount of profit realized in 2019 according to the approved Annual Financial report.; The General Meeting adopts a decision that of 2% (two percent) of the profit realized in 2019 will be distributed among the members of the company's senior management team, subject to the requirements of art. 26a, item 12 of the Articles of Association of the company.; AGM adopts an amendment of the Articles of Association of the Company.; AGM adopts the Substantiated

Report of the Board of Directors for transactions within the scope of art. 114, para 1 of the LPOS.; The AGM authorizes the Board of Directors to conclude a transaction within the scope of art. 114, para 1 of the LPOS - under the terms of Section I,II,III, IV, V и VI of the Substantiated Report.

- On 5 June 2020 the Annual General Meeting of “Sopharma Trading” AD was held, at which the following decisions were taken: The AGM approves of the Annual Report of the Board of Directors on the company's activities in 2019; The AGM approves the Annual Report of the Investor Relations Director for 2019; The AGM approves the Auditor's Report on the audit of the Annual Financial Statements of the Company for 2019; The AGM approves the Annual Financial Statements of the Company for 2019; The AGM approves the Auditor's Report on the audit of the Annual Consolidated Financial Statements of the Company for 2019; The AGM approves the Annual Consolidated Financial Statements of the Company for 2019; The AGM accepts the report of the Board of Directors under art. 12, para 1 of Ordinance № 48 of 20 March 2013 on the requirements for remuneration; The AGM approves the Audit Committee's report in 2019; The AGM approves the proposal of the Board of Directors for distribution of the company's profit, realized in 2019: The net financial result in the amount of BGN 20 095 473.97 / twenty million ninety-five thousand four hundred seventy-three levs and ninety-seven stotinki / to be divided as follows: BGN 2 009 547.40 / two million nine thousand five hundred forty-seven levs and forty stotinki / refers to the Reserve Fund as a 10% required reserve, BGN 10 282 815 / ten million two hundred eighty-two thousand eight hundred and fifteen levs / for distribution of a cash dividend to the shareholders, BGN 7 803 111.57 / seven million eight hundred and three thousand one hundred and eleven levs and fifty-seven stotinki / to be referred as an additional reserve of the company. Dividend amount per gross share - BGN 0.30 / thirty stotinki /. Amount of the dividend per one net share (only for individual shareholders) - BGN 0.285 (only for individual shareholders).; The AGM approves a decision to discharge the members of the Board of Directors for their activity in 2019; The AGM determines a monthly remuneration for each of the members of the Board of Directors for 2020 in the amount of BGN 2,000; The AGM decides to pay the Executive Director of „Sopharma Trading“ AD a variable remuneration in the amount of one percent of the net profit of the company for 2019, according to the approved Annual Financial Statements. The payment of 40% of the remuneration is rescheduled for a period of three years. The payment of the rescheduled part of the variable remuneration is made proportionally, in equal monthly

installments; The AGM elects a registered auditor to be appointed for inspection and certification of the Annual Financial Statements of the Company for 2020 and the consolidated Annual Financial Statements for 2020, according to the proposal of the Audit Committee.; The AGM elects members of the Audit Committee of the company consisting of: Vasil Naidenov, Kristina Atanasova, Zvetelina Stanimirova; The AGM approves the Substantiated Report of the Board of Directors on the expediency and conditions of transactions falling within the scope of Art. 114, para 1 of LPOS, to which the company is a party; The AGM authorizes the Board of Directors of the company to conclude a transaction within the scope of Art. 114, para 1 item 3 of LPOS under the conditions and within the terms, according to sections I to LXIII of the Motivated Report prepared by the Board of Directors.

- On 16 June 2020 a Regular General Meeting of the shareholders of “Sopharma Buildings” REIT was held, at which the following decisions were taken: The AGM approves the Annual Report of the Board of Directors on the company's activities in 2019; The AGM approves presented Annual Report of the Investor Relations Director for 2019; The AGM approves the Audit Report for the performed audit of the Annual Financial Statements of the Company for 2019; The AGM approves the audited Annual Financial Statements of the Company for 2019; The AGM approves the report of the Audit Committee on its activities in 2019; The AGM approves the Report of the Board of Directors on the implementation of the Remuneration Policy for the members of the Board of Directors of the Company for 2019; The AGM approves a decision for distribution of the Company's profit realized in 2019.; The AGM accepts the proposal of the Board of Directors that the Company not distribute a dividend for 2019 due to the fact that the Company has ended the reporting year 2019 with a negative financial result in the amount of BGN 80,026.05 (eighty thousand twenty-six levs and five stotinki) and after transformation by the order of art. 10 of the Special Investment Purpose Companies Act - loss in the amount of BGN 74 825.43 (seventy-four thousand eight hundred and twenty-five leva and forty-three stotinki). The formed loss for 2019 in the amount of BGN 80 026.05 (eighty thousand twenty-six levs and five stotinki) to be covered by the accumulated reserves from the Company's Emission Premium Fund; The AGM re-elects the members of the Audit Committee of the Company for a new term; The AGM determines a monthly remuneration of each of the members of the Audit Committee of the Company in the amount of BGN 400; The AGM releases from liability the members of the Board of Directors of the Company for their activities in 2019; The AGM dismisses Ivan Krlev from the position of a member of the Board of Directors

of the Company due to the expiration of the term and authorizes Irina Mincheva to sign an annex for termination of the management contract.; The AGM re-elects the members of the Board of Directors Emil Kostov and Irina Mincheva for a new term of 5 years and elects as a new member of the Board of Directors of the Company Stoycho Pangev with a term of 5 years; The AGM decided to keep the current amount of the permanent monthly remuneration of the members of the Board of Directors of the Company in 2020 as well; The AGM assigns a guarantee for the management of each of the members of the Board of Directors in the amount of its respective 3-month gross remuneration, which should be paid within seven days from the date of the AGM meeting in compliance with the requirements of Article 116c of LPOS; The AGM authorizes Irina Mincheva to conclude on behalf and for the account of the Company the contracts for assignment of the management of the Company with the members of the Board of Directors, outside the executive member, as well as any subsequent annexes to them, including the right to negotiate with itself; The AGM selects a specialized auditing company "Baker Tilly Klitou and Partners" OOD as a registered auditor for 2020, according to the recommendation of the Audit Committee.

- On 10 August 2020 the Annual General Meeting of "Momina krepost" AD – Veliko Tarnovo was held, at which the following decisions were taken: The AGM approves the Annual report of the Board of Directors on the activities of the Company in 2019 together with the Corporate governance declaration for 2019.; The AGM approves the Annual Report of the Investor Relations Director for 2019; The AGM approves the Auditor's Reports on the Audit of the Annual Financial Statements of the Company for the year 2019; The AGM approves the Audited Annual Financial Statements of the Company for 2019.; The AGM approves the Audit Committee's report on its activities in 2019.; The AGM accepts the proposal of the Board of Directors to cover the loss for 2019 in the amount of BGN 546 thousand of the retained earnings of the Company; The AGM releases the members of the Board of Directors from responsibility for their activities in 2019.; The AGM elects a registered auditor for inspection and certification of the Annual Financial Statements of the Company for 2020, according to the proposal of the Audit Committee, included in the materials on the agenda; The AGM approves the Report of the Board of Directors on the implementation of the Remuneration Policy of the Members of the Board of Directors of "Momina Krepost"AD for 2019.; The AGM decided to keep the current amount of the constant monthly remuneration of the Chairman of the Board of Directors and the members of the Board of Directors and in 2020.; The AGM decided the amount of the

monthly remuneration under the management contract of the Executive Director to be BGN 3,000.; The AGM dismisses Stoyan Valchinov Garov as a member of the Board of Directors; The AGM elects Valchin Stoyanov Garov as a member of the Board of Directors of the company.

- With Decision № 626 / 23.07.2020 the Commission for Protection of Competition of the Republic of Bulgaria authorized the concentration within the meaning of Chapter V of the Law on Protection of Competition by acquiring sole control by “Sopharma Trading” AD over CSS Franchise AD and Sanita Franchising AD. Immediate execution of the decision was also ordered. A condition for finalizing the acquisition is the authorization by the General Meeting of Shareholders of “Sopharma Trading” AD.
- On 3 August 2020 “Sopharma” AD started the payment of the dividend in the amount of 7 stotinki per share, voted at the Regular General Meeting of Shareholders held on 05.06.2020. The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the Annual General Meeting, i.e. June 19, 2020. In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary – through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Postbank in the country until October 30, 2020 (after that date, shareholders who have not received their dividend in the appropriate order may do that at the cash desk of the Company in Sofia, 16 Iliensko Shose Str. every business day between 10:00 a.m. - 12:00 p.m. and 14:00 p.m. - 16:00 p.m., tel. 02/ 8134 283).
- On 4 August 2020 a merger of “Sopharma Trading Pharmaceuticals” D.o.o. was registered in “Sopharma Trading” D.o.o., by merging the assets and liabilities of the two companies. The activity of the merged company “Sopharma Trading Pharmaceuticals” D.o.o. is terminated and all its rights and obligations at the time of the merger are assumed by Sopharma Trading” D.o.o.
- At the Extraordinary General Meeting of Shareholders of Sopharma Buildings REIT, which was held on 24.09.2020, the following decision was made: GMS adopts the new Remuneration Policy developed and proposed by the Board of Directors of the members of the Board of Directors of Sopharma buildings “REIT.
- On 25 September 2020, an Extraordinary General Meeting of the Shareholders of Sopharma AD was held, at which the following decisions were taken: The GMS accepted

the proposal of the Board of Directors to distribute a 6-month gross dividend to the shareholders in the amount of BGN 0.04 / four stotinki / per share. The right to receive a dividend have the persons entered in the register of Central Depository AD as shareholders on the 14th day after the day of the General Meeting, at which the 6-month financial report for the first half of 2020 was adopted and a decision was made for distribution of profits, namely October 9, 2020 (dividend record date). Ex-dividend date - October 8, 2020 (ex-dividend date). The dividend payment will start on November 23, 2020 (Monday). In accordance with the Regulations of Central Depository AD, the dividend will be paid as follows: for the shareholders who have opened client accounts with investment intermediaries - through the respective investment intermediary; for shareholders without accounts with investment intermediaries - through the branches of Eurobank and FG - Bulgaria AD / Postbank / in the country. The General Meeting adopted a new remuneration policy in accordance with Ordinance №48 of March 20, 2013 of the Financial Supervision Commission / promulgated, SG, iss. 32 of 2.04.2013, amended and add., no. 41 of 21.05.2019, amended no. 66 of 20.08.2019, amended and add., no. 61 of 10.07.2020 / and Article 116 "c" of the Law on Public Offering of Securities.

- On 25.09.2020 an Extraordinary General Meeting of the shareholders of Sopharma Trading AD was held, at which the following decisions were taken: 1. The GMS approves the Motivated Report of the Board of Directors on the expediency and conditions of transactions within the scope of Art. 114, para. 1 of LPOS; 2. The GMS authorizes the Board of Directors of the company to conclude a transaction within the scope of art. 114, para. 1, item 1 of the LPOS under the conditions and terms, according to Section I of the Motivated Report prepared by the Board of Directors; 3. No decision was taken on this point; 4. The GMS approves changes in the remuneration policy of the members of the Board of Directors of Sopharma Trading AD in accordance with the amendments to Ordinance №48 of the FSC, promulgated in SG, issue 61 of July 10, 2020.
- On 28 September 2020, an Extraordinary General Meeting of the shareholders of Momina Krepost AD - Veliko Tarnovo was held, which adopted the changes in the Remuneration Policy in Momina Krepost AD.
- On 1 October 2020 "Sopharma Trading" AD finalized the acquisition of sole control over the companies "SCS Franchise" AD and "Sanita Franchising" AD. The announcement comes after the Commission for Protection of Competition approved the deal in the end of July, ordering the immediate execution of the decision. A condition for its completion was the authorization by the General Meeting of Shareholders of "Sopharma Trading" AD, which

30

This is a translation from Bulgarian of the Management report of Sopharma Group for the nine months of 2020.

In case of divergence Bulgarian text should prevail.

took place on 25.09.2020. The conditions under which the shares of “SCS Franchise” AD was acquired are fully compliant with the decision of the General Meeting of Shareholders of Sopharma Trading AD.

- On 13 October 2020 “Sopharma” AD acquired an additional 5.01% of the capital of “Aromania” AD.

6. Transactions with related parties

The information concerning transactions with related parties is presented in details in the Notes to the financial report.

III. Information about the shares of “Sopharma” AD

The total number of shares emitted by “Sopharma” AD, issued on 30.09.2020, is 134 797 899 with a nominal value of BGN 1 per share. All issued shares are registered, dematerialized, ordinary and indivisible, according to the Articles of Association of the Company. All issued shares are of one class. Each share gives equal rights to its holder in proportion to the nominal value of the share.

The shares of the Company are traded on the Bulgarian “Stock Exchange – Sofia” AD, the Main Market (BSE), the PREMIUM Shares Market and on the official market of the Warsaw Stock Exchange. The shares participate in the formation of the SOFIX, BGBX40 and BGTR30 indices of BSE - Sofia AD. The company's shares are included in the Dow Jones STOXX EU Enlarged Total Market Index with a weight of 0.11%, with a weight of 5% in Erste Bank Bulgaria Basket, in the Raiffeisen Bank's Raiffeisen Osteuropa Fonds certificate as well as in the new Dow blue-chip index Jones STOXX Balkan 50 Equal Weighted Index. “Sopharma” AD is one of the three Bulgarian companies included in the Central and Eastern Europe (CEE) Index. The index is called WIG-CEE and is the third after WIG-Poland and WIG-Ukraine, which is based on the country's country of origin. WIG-CEE is calculated on a common yield basis and includes dividend yield and share subscription rights.

Key indicators of the shares of “Sopharma” AD

	30.09.2020	30.06.2020
Total number of issued shares	134 797 899	134 797 899
Average-weighted number of outstanding shares for the last four quarters	125 767 240	125 817 480
Number of shares outstanding at the end of the period	125 851 432	125 769 432
Earnings per share in BGN ¹	0,597	0,285
Price per share at the end of the period in BGN	3,08	3,167

31

This is a translation from Bulgarian of the Management report of Sopharma Group for the nine months of 2020.

In case of divergence Bulgarian text should prevail.

Sopharma Group

Price/Earnings ratio (P/E)	5,16	11,11
Book value per share in BGN ²	4,464	4,246
Price/Book value ratio (P/B)	0,69	0,75
Market capitalization at the end of the period in BGN	415 177 529	385 772 551

¹ Net profit for the last four quarters belonging to the owners of the Company's equity / weighted average number of outstanding shares for the same period

² Equity other than minority interest / number of outstanding shares at the end of the period

³ Sales revenue for the last four quarters / number of outstanding shares at the end of the period

Trade with shares of “Sopharma” AD on “Bulgarian Stock Exchange – Sofia” AD for the period 1 January 2020 – 30 September 2020:



30.11.2020
Sofia

/Signature/

.....

Ognian Donev, PhD
/Executive Director/